Cellectar Biosciences, Inc.
CLRB
$2.36
-$0.15-5.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.29M | 11.48M | 15.48M | 20.99M | 23.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.37M | 22.98M | 30.03M | 38.51M | 46.18M |
| Operating Income | -22.37M | -22.98M | -30.03M | -38.51M | -46.18M |
| Income Before Tax | -20.84M | -21.79M | -18.79M | -29.01M | -24.48M |
| Income Tax Expenses | -- | -- | 66.00K | 66.00K | 66.00K |
| Earnings from Continuing Operations | -20.84 | -21.79 | -18.85 | -29.07 | -24.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.84M | -21.79M | -18.85M | -29.07M | -24.54M |
| EBIT | -22.37M | -22.98M | -30.03M | -38.51M | -46.18M |
| EBITDA | -22.16M | -22.77M | -29.80M | -38.26M | -45.92M |
| EPS Basic | -7.41 | -10.38 | -10.78 | -20.55 | -17.94 |
| Normalized Basic EPS | -4.63 | -6.49 | -6.71 | -12.82 | -11.18 |
| EPS Diluted | -7.42 | -10.39 | -10.78 | -21.51 | -23.54 |
| Normalized Diluted EPS | -4.63 | -6.49 | -6.71 | -12.74 | -11.08 |
| Average Basic Shares Outstanding | 13.12M | 10.42M | 7.70M | 5.85M | 5.44M |
| Average Diluted Shares Outstanding | 13.12M | 10.42M | 7.70M | 5.87M | 5.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |